130 related articles for article (PubMed ID: 2312600)
1. Multiple myeloma: biology and therapy.
Barlogie B; Epstein J
J Cancer Res Clin Oncol; 1990; 116(1):109-11. PubMed ID: 2312600
[No Abstract] [Full Text] [Related]
2. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
3. [Could the VAD protocol be the first line therapy for multiple myeloma in subSaharan Africa? The Brazzaville experience].
Dokekias AE
Sante; 2011; 21(3):169-70. PubMed ID: 22396958
[No Abstract] [Full Text] [Related]
4. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?
Dimopoulos MA; Kastritis E
Leuk Lymphoma; 2006 Nov; 47(11):2271-2. PubMed ID: 17107895
[No Abstract] [Full Text] [Related]
5. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
6. The treatment of multiple myeloma.
Alexanian R; Dimopoulos M
N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
[No Abstract] [Full Text] [Related]
7. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH
Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507
[TBL] [Abstract][Full Text] [Related]
8. Amyloid deposition of systemic myeloma-associated amyloidosis excludes actinic elastotic material.
Wada N; Fujimoto N; Komatsu T; Tajima S; Ishibashi A
Eur J Dermatol; 2002; 12(6):607-8. PubMed ID: 12459542
[TBL] [Abstract][Full Text] [Related]
9. High dose dexamethasone as first line therapy of multiple myeloma? A case report.
Meregalli M; Bertola G; Grando D
Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388
[TBL] [Abstract][Full Text] [Related]
10. VAD followed by VMCP: an alternative regimen for multiple myeloma.
Wadhwa J; Kumar L; Kochupillai V
Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
[TBL] [Abstract][Full Text] [Related]
11. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Hussein MA
Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
[TBL] [Abstract][Full Text] [Related]
12. VAD-based regimens as primary treatment for multiple myeloma.
Alexanian R; Barlogie B; Tucker S
Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376
[TBL] [Abstract][Full Text] [Related]
13. Bilateral transient hearing loss associated with vincristine therapy: case report.
Aydogdu I; Ozturan O; Kuku I; Kaya E; Sevinc A; Yildiz R
J Chemother; 2000 Dec; 12(6):530-2. PubMed ID: 11154039
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
15. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.
van de Donk NW; de Weerdt O; Veth G; Eurelings M; van Stralen E; Frankel SR; Hagenbeek A; Bloem AC; Lokhorst HM
Leukemia; 2004 Jun; 18(6):1078-84. PubMed ID: 15085157
[TBL] [Abstract][Full Text] [Related]
16. Fever as presenting symptom of multiple myeloma.
Pitz CC; Lokhorst HM; Hoekstra JB
Neth J Med; 1998 Dec; 53(6):256-9. PubMed ID: 9883003
[TBL] [Abstract][Full Text] [Related]
17. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
Maniatis A; Stamatellou M; Papanastasiou K
Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
[No Abstract] [Full Text] [Related]
19. Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma.
Becker PS
J Clin Oncol; 2011 Mar; 29(7):783-6. PubMed ID: 21245424
[No Abstract] [Full Text] [Related]
20. Gastric invasion of multiple myeloma presenting as gastrointestinal bleeding.
Nakajima K; Sueki Y; Koshiishi M; Kawashima I; Nozaki Y; Mitsumori T; Kirito K
Int J Hematol; 2015 Jun; 101(6):525-6. PubMed ID: 25916464
[No Abstract] [Full Text] [Related]
[Next] [New Search]